No active 13F manager changed its position in Insight Molecular Diagnostics Inc. last quarter. Over the last 180 days, 1 insider bought and none sold, a net +$2.7M in open-market trades.
The legs disagree, or only one of them leans.
Not held in any tracked 13F filing yet.
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Apr 27, 2026 | Broadwood Partners, L.p. | 10% Owner | Buy (P) 2 lots, same day | 251K | $913K |
| Apr 24, 2026 | Broadwood Partners, L.p. | 10% Owner | Buy (P) 2 lots, same day | 39K | $137K |
| Apr 23, 2026 | Broadwood Partners, L.p. | 10% Owner | Buy (P) 2 lots, same day | 280K | $982K |
| Apr 20, 2026 | Broadwood Partners, L.p. | 10% Owner | Buy (P) 2 lots, same day | 41K | $158K |
| Apr 17, 2026 | Broadwood Partners, L.p. | 10% Owner | Buy (P) 2 lots, same day | 40K | $143K |
| Apr 16, 2026 | Broadwood Partners, L.p. | 10% Owner | Buy (P) 2 lots, same day | 102K | $352K |
| Feb 10, 2026 | Bradsher Neal C | 10% Owner | Buy (P) 2 lots, same day | 522K | $3.0M |
| Feb 7, 2025 | James Andrea S. | Chief Financial Officer | Buy (P) | 98K | $200K |
| Feb 7, 2025 | Smith Patrick W | 10% Owner | Buy (P) | 1.1M | $2.2M |
| Feb 6, 2025 | Broadwood Partners, L.p. | 10% Owner | Buy (P) 4 lots, same day | 5.2M | $10.6M |
| Feb 4, 2025 | Smith Patrick W | 10% Owner | Buy (P) | 25 | $51 |
| Jan 31, 2025 | Smith Patrick W | 10% Owner | Buy (P) | 890 | $2K |
One row per insider, day and transaction code; shares and value are summed across the lots. Every lot is on the full insider page and in the filing.
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 0 | 0 | – |
Insiders Form 4 open-market | 1 | 0 | +$2.7M |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for Insight Molecular Diagnostics Inc.
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/OCX/capital-change-brief"
Use Arkolith's capital_change_brief for Insight Molecular Diagnostics Inc.. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + the live filing stream, joined for OCX. Filings are public domain, sourced to SEC EDGAR.